Aveo Capital Partners’s Viridian Therapeutics VRDN Stock Holding History

Aveo Capital Partners’s Portfolio VRDN Stock Details VRDN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-1,115	Closed	-$13K	–	179
2020 Q3	$13K	Hold	1,115	–	–	﹤0.01%	191
2020 Q2	$19K	Hold	1,115	–	–	0.04%	58
2020 Q1	$7K	Hold	1,115	–	–	﹤0.01%	156
2019 Q4	$8K	Hold	1,115	–	–	﹤0.01%	186
2019 Q3	$13K	Hold	1,115	–	–	0.01%	180
2019 Q2	$35K	Hold	1,115	–	–	0.02%	182
2019 Q1	$47K	Hold	1,115	–	–	0.02%	165
2018 Q4	$51K	Hold	1,115	–	–	0.03%	128
2018 Q3	$77K	Hold	1,115	–	–	0.03%	137
2018 Q2	$107K	Hold	1,115	–	–	0.05%	137
2018 Q1	$117K	Sell	1,115 -667	-37%	-$72.5K	0.05%	138
2017 Q4	$279K	Buy	+1,782	New	+$227K	0.09%	105

Other funds holding VRDN

LGM

Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

AVA

Atlas Venture Advisors Boston, Massachusetts $122M AUM 26.28% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Aveo Capital Partners's VRDN Position: Q4 2020 in Review

Aveo Capital Partners sold out of Viridian Therapeutics (VRDN) in Q4 2020, closing a stake of 1,115 shares — an estimated $13K sold.

Aveo Capital Partners first reported a position in VRDN in Q4 2017 and held it in 12 quarters. The position peaked at $279K in Q4 2017. 22 funds tracked by Wall St. Rank hold VRDN as of Q4 2020.

Aveo Capital Partners reported no remaining Viridian Therapeutics position as of Q4 2020 after selling out during the quarter.
Aveo Capital Partners sold 1,115 Viridian Therapeutics shares in Q4 2020, an estimated $13K.
Aveo Capital Partners first reported a position in Viridian Therapeutics in Q4 2017 and held it in 12 quarters.
Aveo Capital Partners's Viridian Therapeutics position peaked at $279K in Q4 2017.
22 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q4 2020.

Based on Aveo Capital Partners's 13F filing for Q4 2020, filed 10 Feb 2021.